References

emcardio

Неотложная кардиология и кардиоваскулярные риски

Emergency Cardiology and Cardiovascular Risks journal

2616-633X

Белорусский государственный медицинский университет

10.51922/2616-633X.2021.5.2.1395

emcardio-164

Research Article

Обзоры и лекции

Reviews and lectures

Пожилой пациент с острым коронарным синдромом: особенности ведения в период пандемии COVID-19

An elderly patient with acute coronary syndrome: management during COVID-19 pandemic

Цапаева

Н. Л.

Tsapaeva

N. L.

Петрова

Е. Б.

Petrova

E. B.

Плешко

А. А.

Pleshko

A. A.

УО «Белорусский государственный медицинский университет»Belarusian State Medical University

ГУ «Республиканский научно-практический центр «Кардиология»Republican Scientific and Practical Center Cardiology

2021

24102025

1395–1405

2025

Цапаева Н.Л., Петрова Е.Б., Плешко А.А.

Tsapaeva N.L., Petrova E.B., Pleshko A.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://emcardio.bsmu.by/jour/article/view/164

Увеличение количества пожилых людей в медицинском аспекте – это преобладание в структуре заболеваемости патологии, которая определяется коморбидностью, системностью поражения и неблагоприятным прогнозом. Коморбидные пациенты являются наиболее уязвимой группой, у которой риск фатальных исходов особенно высок. В представленном обзоре рассмотрена проблема ведения острого коронарного синдрома (ОКС) у пожилых пациентов в условиях пандемии COVID-19. Приведены результаты рандомизированных клинических исследований и регистров последних лет, целенаправленно включивших пациентов с ОКС пожилого возраста. Особое внимание уделено необходимости гериатрической оценки пациентов, наличию и выраженности старческой астении и ее влиянию на выбор тактики лечения и прогноз. Рассмотрена проблема выбора метода реваскуляризации миокарда и схем медикаментозной терапии у пожилых пациентов в условиях пандемии. Отражены вопросы, касающиеся лекарственного взаимодействия препаратов для лечения острых форм ишемической болезни сердца и препаратов для лечения COVID-19. В этой ситуации особое значение имеет учет рисков возможных межлекарственных взаимодействий, что особенно актуально у пожилых коморбидных пациентов. Рассмотрены основные тенденции в выборе тактики лечения пожилых пациентов с ОКС в период пандемии COVID-19

An increased number of elderly people in the medical terms means the predominance of pathology in the morbidity structure, which is determined by comorbidity, systemic lesions and an unfavorable prognosis. Comorbid patients are the most vulnerable group with a particularly high risk of adverse outcomes. In the presented review, the problem of management of acute coronary syndrome (ACS) in elderly patients in the context of the COVID-19 pandemic is addressed. The review demonstrates results of randomized clinical trials and registries of recent years, which purposefully included patients with ACS aged ≥ 75 years. Particular attention is paid to the need for a geriatric assessment of patients, the presence and severity of senile asthenia and its influence on the choice of treatment tactics and prognosis. The problem of choosing a method of myocardial revascularization and drug therapy schemes in elderly patients is considered under pandemic conditions. Issues related to drug interactions between drugs for the treatment of acute forms of coronary heart disease and drugs for the treatment of COVID-19 are reflected. In this situation, taking into account the risks of possible drug-drug interactions is of particular importance, which is especially challenging in elderly comorbid patients. Based on the available data, we have analyzed the main trends in the choice of treatment tactics for elderly patients with ACS during the COVID-19 pandemic.

острый коронарный синдромкоронавирусная инфекцияCOVID-19пожилой пациентгериатрический синдромреваскуляризация миокардаантитромботическая терапия

acute coronary syndromeCOVID-19elderly patientsgeriatric syndromemyocardial revascularizationantithrombotic therapy

References1

Department of Economic and Social Affairs, Population Division. World Population Ageing 2015 [electronic resource]. New York, 2015, 164 p.

Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020, vol. 323(13), pp. 1239-1242. doi:10.1001/jama.2020.2648.

Zheng Y.Y., Ma Y.T, Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020, vol. 17(5), pp. 259-260. doi:10.1038/s41569-020-0360-5.

Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395(10223), pp. 497-506. doi:10.1016/S0140-6736(20)30183-5.

Inciardi R.M., Lupi L., Zaccone G., Italia L., Raffo M., Tomasoni D., Cani D.S., Cerini M., Farina D., Gavazzi E. et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol, 2020, vol. 5(7), pp.819-824. doi:10.1001/jamacardio.2020.1096.

Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X., Zhang Q., Wu J. Coronavirus infections and immune responses. Med Virol, 2020, vol. 92(4), pp. 424-432. doi:10.1002/jmv.25685.

Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol, 2017, vol. 39(5), pp. 529-539. doi:10.1007/s00281-017-0629-x.

Сердечно-сосудистые события у пациентов с новой коронавирусной инфекцией COVID-19 / А.А. Плешко [и др.] // Кардиология в Беларуси. – 2021. – Т. Выпуск 4 2021. – С. 580-595. https://doi.org/10.34883/PI.2021.13.4.007

Suaya J.A., Stason W.B., Ades P.A. Normand S-L.T., Shepard D.S. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol, 2009, vol. 54(1), pp. 25-33.

WHO (2017). Dementia [electronic resource]. Available at: http://www.who.int/news-room/factsheets/detail/dementia.

WHO (2017). Mental health of older adults. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/mentalhealth-of-older-adults.

Lee P.Y., Alexander K.P., Hammill B.G., Pasquali S.K., Peterson E.D. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA, 2001, vol. 286(6), pp. 708-713.

Gilyarov M.Y., Zheltoukhova M.O., Konstantinova E.V., Muksinova M.D., Muradova L.S., Nesterov A.P., Udovichenko A.E. Osobennosti lecheniya ostrogo koronarnogo sindroma u pozhilyh: opyt gorodskoj klinicheskoj bolnicy №1 im. N.I. Pirogova [Treatment characteristics of acute coronary syndrome in elderly patients: practice of N.I. Pirogov city clinical hospital №1]. Ratsionalnaya farmakoterapiya v kardiologii, 2017, vol. 13(2), pp. 164-170. (in Russian).

Dai X., Busby-Whitehead J., Alexander K.P. Acute coronary syndrome in the older adults. J Geriatr Cardiol, 2016, vol. 13(2), pp. 101-108. doi: 10.11909/j.issn.1671-5411.2016.02.012.

Gale C.P., Cattle B.A., Woolston A., Woolston A., Baxter P.D., West T.H., Simms A.D., Blaxill J., Greenwood D.C., Fox K.A.A., Westet R.M. Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003-2010. Eur Heart J, 2012, vol. 33(5), pp. 630-639. doi: 10.1093/eurheartj/ehr381.

Bach R.G., Cannon C.P., Weintraub W.S., DiBattiste P.M., Demopoulos L.A., Anderson H.V., DeLucca P.T., Mahoney E.M., Murphy S.A., Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med, 2004, vol. 141(3), pp. 186-195.

Tegn N., Abdelnoor M., Aaberge L., Endresen K., Smith P., Aakhus S., Gjertsen E., Dahl-Hofseth O., Ranhoff A.H., Gullestad L., Bendz B. After Eighty study investigators. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet, 2016, vol. 387(10023), pp. 1057-1065. doi: 10.1016/S0140-6736(15)01166-6.

Tkacheva O.N., Kotovskaya Yu.V., Feoktistova K.V., Ostapenko V.S., Osadchiy I.A., Khokhlunov S.M., Runikhina N.K., Dyplyakov D.V. Ostryj koronarnyj sindrom v starcheskom vozraste: status problemy i nereshennye voprosy [Acute coronary syndrome in elderly: current status and unresolved issues]. Kardiovaskulyarnaya terapiya i profilaktika, 2017, vol. 16(3), pp. 62-67. doi: 10.15829/1728-8800-2017-3-62-67. (in Russian).

Angeli F., Verdecchia P., Savonitto S., Morici N., De Servi S., Cavalliniet C. Early invasive versus selectively invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: impact of age. Catheter Cardiovasc Interv, 2014, vol. 83(5), pp. 686-701. doi: 10.1002/ccd.25307.

Schiele F., Meneveau N., Seronde M.F., Descotes-Genon V., Oettinger J., Ecarnot F., Bassand J.P. Reseau de Cardiologie de Franche Comte. Changes in management of elderly patients with myocardial infarction. Eur Heart J, 2009, vol. 30(8), pp. 987-894.

Petroni T., Zaman A., Georges J.L., Hammoudi N., Berman E., Segev A., Juliard J.M., Barthelemy O., Silvain J., Choussat R., Claude Le Feuvre 1, Gérard Helft 1 et al; Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians. Heart, 2016 vol. 102: 1648-1654.

Armstrong P.W., Gershlick A.H., Goldstein P., Wilcox R., Danays T., Lambert Y., Sulimov V., Ortiz F.R., Ostojic M., Welsh R.C. et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med, 2013, vol. 368(15), pp. 1379-1387.

White H.D., Braunwald E., Murphy S.A., Jacob A.J., Gotcheva N., Polonetsky L., Antman E.M. Enoxaparin vs. Unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACTTIMI 25. Eur Heart J, 2007, vol. 28(9), pp. 1066-1071.

Thiemann D.R., Coresh J., Shulman S.P., Gerstenblith G., Oetgen W.J., Powe N.R. Lack of Benefit for Intravenous Thrombolysis in Patients With Myocardial Infarction Who Are Older Than 75 Years. Circulation, 2000, vol. 101(19), pp. 2239-2246.

Клинический протокол диагностики и лечения инфаркта миокарда, нестабильной стенокардии Приложение 2 к постановлению Министерства здравоохранения Республики Беларусь 06.06. 2017 № 59, С 43-92.

Рекомендации ESC по ведению пациентов с острым коронарным синдромом без стойкого подъема сегмента ST 2020. Российский кардиологический журнал, 2021; 26 (3). С125-193 doi:10.15829/1560-4071-2021-4418.

Староверов И.И., Шахнович Р.М., Гиляров М.Ю., Комаров А.Л., Константи нова Е.В., Панченко Е.П., Явелов И.С. Евразийские клини ческие рекомендации по диагностике и лечению острого коронарного синдрома с подъемом сегмента ST (ОКСпST). Евразийский кардиологический журнал. 2020;(1):4-77. https://doi.org/10.38109/2225-1685-2020-1-4-77.

Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020, vol. 323(11), pp. 1061-1069. doi:10.1001/jama.2020.1585.

Husted S., James S., Becker R.C., Becker R.C., Horrow J., Katus H., Storey R.F., Cannon C.P., Heras M., Lopes R.D., Morais J., Mahaffey K.W., Bach R.G., Wojdyla D., Wallentin L. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes, 2012, vol. 5(5), pp. 680-688.

Wiviott S.D., Braunwald E., McCabe C.H. et al. Prasugrel versus сlopidogre in рatients with аcute сoronary syndromes. N Engl J Med, 2007, vol. 357(20), pp. 2001-2015.

Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S., Pfeffer M., Hohnloser S., Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet, 2006, vol. 367(9526), pp. 1903-1912. doi: 10.1016/S0140-6736(06)68845-4.

Lopes R.D., Rao M., Simon D.N., Thomas L., Ansell J., Fonarow G.C., Gersh B.J., Go A.S., Hylek E.M., Kowey P., Piccini J.P., Singer D.E., Chang P., Peterson E.D., Mahaffey K.W. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med, 2016, vol. 129(6), pp. 592-599. doi: 10.1016/j.amjmed.2015.12.026.

Capodanno D., Angiolillo D.J. Antithrombotic therapy in the elderly. J Am Coll Cardiol, 2010, vol. 56(21), pp. 1683-1692. doi: 10.1016/j.jacc.2010.04.063.

Tikellis C., Thomas M.C. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int J Pept. 2012. doi:10.1155/2012/256294.

Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 2020, vol. 17, pp, 259-260; doi:10.1038/s41569-020-0360-5.

Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res, 2020, vol. 81(5), pp. 537-540. doi:10.1002/ddr.21656.

Bozkurt B., Kovacs R., Harrington B. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. J Card Fail, 2020, vol. 26(5), pp. 370.

Catapano A.L., Graham I., de Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016, vol. 37(39), pp. 2999-3058. doi: 10.1093/eurheartj/ehw272.

Waters D.D., Guyton J.R., Herrington D.M., McGowan M.P., Wenger N.K., Shear C. et al. Treating to New Targets (TNT) Study: does lowering lowdensity lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol, 2004, vol. 93(2), pp. 154-158.

2019 Рекомендации ЕSC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска // Российский кардиологический журнал 2020; 25 (5). С. 121-193.

Shrestha S.K. Statin drug therapy may increase COVID-19 infection. NMJ, 2020, vol. 3(1).

Ryzhkova Y., Kanareykina E., Atabegashvili M., Konstantinova E., Gilyarov M. Ostryj koronarnyj sindrom u pozhilyh: osobennosti vedeniya pacientov [Acute coronary syndrome in elderly: aspects of patient management. Klinitsist]. Klinicist, 2019, vol. 13(1-2), pp. 19–26. doi: 10.17650/1818-8338-2019-13-1-2-19-26. (in Russian).

De Alencar Neto J.N. Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence- based Review. Cureus, 2018, vol. 10(1), pp. 2114. doi: 10.7759/cureus.2114.

Soukoulis V., Boden W.E., Smith S.C., O’Gara P.T. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res, 2014, vol. 114(12), pp. 1944-1958.

The authors declare that there are no conflicts of interest present.